• 1
    O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002; 20: 28122823.
  • 2
    Garber AM. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Affairs. 2004; Web Exclusive. Available from URL: [accessed May 19, 2004].
  • 3
    Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. JAMA. 1996; 276: 13391341.
  • 4
    Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996; 276: 12531258.
  • 5
    Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993; 13: 322338.
  • 6
    World Health Organization. World Health Organization handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
  • 7
    Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999; 17: 485493.
  • 8
    Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000; 18: 13371345.
  • 9
    Miller RG Jr. Survival analysis. Wiley series in probability and mathematical statistics: applied probability and statistics. New York: John Wiley & Sons, Inc., 1981.
  • 10
    Red Book™ for Windows®. Greenwood, CO: Thomson Micromedex, 2003.
  • 11
    Hospital statistics 2001. American Hospital Association. Available from URL: [accessed date, year].
  • 12
    Mutual of Omaha. Current trends in health care and dental costs utilization. Available from URL: [accessed May 5, 2005].
  • 13
    Healthcare Cost and Utilization Project (HCUPnet). Agency for healthcare research and quality. Available from URL: [accessed May 5, 2005].
  • 14
    Brown RE, Hutton J. Cost utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs. 1998; 9: 899907.
  • 15
    Launois R, Reboul-Marty J, Henry B, Bonneterre J. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics. 1996; 10: 504521.
  • 16
    Hutton J, Brown R, Borowitz M, Abrams K, Rothman M, Shakespeare A. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics. 1996; 9(Suppl 2): 822.
  • 17
    Medicode national fee analyzer. Salt Lake City: Ingenix, 2001.
  • 18
    Gold MR, Siegel JE, Russell LB, Weinstein M. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
  • 19
    @Risk. Version 4.5.1. Newfield, NY: Palisade Corporation.
  • 20
    Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000; 18: 33023317.
  • 21
    Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997; 16: 131.
  • 22
    Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? JAMA. 2003; 163: 16371641.